After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $18.0 and $26.0 for Pfizer, spanning the last three months.

Pfizer Inc. is under the legal spotlight as Enanta Pharmaceuticals launches a patent infringement suit that might ripple ...

Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

Pfizer’s oncology division is not only a significant revenue generator but also a cornerstone of its long-term growth strategy. In 2025, oncology sales accounted for over 25% of Pfizer’s total ...

Looking into the current session, Pfizer Inc. (PFE) shares are trading at $25.84, after a 0.39% increase. Moreover, over the ...

Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It ...

Enanta Pharmaceuticals ( ($ENTA) ) has shared an announcement. On August 20, 2025, Enanta Pharmaceuticals announced it filed a patent infringement ...

Pfizer's forward dividend yield currently stands at 6.86%. This yield is so attractive that I wondered if it's the highest of ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer's stock rose 8.03%, despite bearish technicals and mixed analyst ratings. Technical indicators signal a bearish ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.